Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/APREPITANT QILU 125 MG CAPSULAS DURAS EFG

Approved

STANDARD

APREPITANT QILU 125 MG CAPSULAS DURAS EFG

Qilu Pharma Spain S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jan 14, 2021
Approval ID: 3848adf36537a59a
Company: Qilu Pharma Spain S.L.
Type: Standard

Approval Details

Approval Id: 3848adf36537a59a
Drug Cima Aemps Name: APREPITANT QILU 125 MG CAPSULAS DURAS EFG
Register Number: 85688
Holder Company Name: Qilu Pharma Spain S.L.
Marketing Company Name: Qilu Pharma Spain S.L.
Holder Company Detail Path: /organization/qilu-pharma-spain-sl
Marketing Company Detail Path: /organization/qilu-pharma-spain-sl
Authorization Date: 2021-01-14
Dosage Form: CÁPSULA DURA
Dose: 125 mg
Route Of Administration: VÍA ORAL
Prescription Type: Uso Hospitalario
Commercialized: No
Company Name: Qilu Pharma Spain S.L.
Company Detail Path: /organization/qilu-pharma-spain-sl

Company Information

Pharmaceutical Company Name: QILU PHARMA SPAIN SL.
Country Name: Spain
City Name: madrid,madrid,country_es
Address: PASEO CASTELLANA, 40 - PISO 8

Active Ingredients

APREPITANT

125 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jan 14, 2021

Approval ID

3848adf36537a59a

Type

Standard

Back to CIMA-AEMPS Approvals

APREPITANT QILU 125 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details